Impact of COVID-19 on Antibiotics Market Continuing Service Excellence

Increased antibiotic consumption in low- and small-sized countries around the world plays an important role in the growth of the antibiotic market. In addition, an increase in the prevalence of epidemics is expected to stimulate market growth in the coming years.

The antibiotic market is expected to reach $5,374 million by 2025, an annual average growth of 2.1% from 2018 to 2025. Beta-lactam and beta-lactamase inhibitors accounted for more than 3/5 of the total market share in 2017.

Antibiotics are drugs used to suppress or prevent bacterial infections, respectively, called bactericidal and bacteriostatic antibiotics. Various types of antibiotics, such as penicillin, cephalosporins, carbafe em, and monobactam, are available in pharmacies and hospitals used to treat infectious diseases.

Click here to access the free sample report: https://www.alliedmarketresearch.com/request-sample/5072

The antibiotic market is expected to grow significantly during the forecast period due to the increased demand for next-generation antibiotics that can solve the antibiotic resistance problem. In addition, the development of new approaches to new antibiotics for the treatment of bacterial infections and the increasing number of clinical trials complement the growth of the antibiotic market. However, the time it takes to develop antibiotic resistance due to misuse of antibiotics and regulatory approvals curbs market growth. Conversely, the discovery of advanced prospect molecules and the introduction of new combination therapies to treat antibiotic-resistant microbial infections are expected to provide new opportunities for market participants in the near future.

know more: https://www.alliedmarketresearch.com/antibiotics-market

The global antibiotic market is classified by beta-lactam and beta-lactamase inhibitors, quinolone, macrolides, and others on a class basis. The quinolone segment is expected to show the highest CAGR during the forecast period due to a surge in demand for a wide range of bactericidal actions. Next-generation quinolone; Improved oral bioavailability; Good tissue penetration; Safety and tolerability have been improved.

Depending on the route of administration, the market is divided into oral, intravenous and other. The intravenous sector was a major source of income in 2017, and this trend is expected to continue during the forecast period due to the increased incidence of serious infections. Moreover, intravenous antibiotics reach tissues faster than oral antibiotics when administered at higher concentrations.

The Asia Pacific region is expected to dominate during the forecast period due to increased consumption of antibiotics, ease of availability and increased sales of over-the-counter medicines. However, LAMEA is expected to experience the highest growth rate during the forecast period, mainly because it is not obligated to use antibiotics in this region.

This report provides a comprehensive analysis of key players in the global antibiotic market, including Abbott Laboratories, Allergan Plc., F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co., Mylan NV, Novartis International. AG (Sandos), Pfizer, Sanofi, Teva Pharmaceutical Industries

Other companies in the value chain include Aurobindo Pharma, Bayer HealthCare, Eli Lilly, Lupine Pharmaceuticals, Sun Pharmaceutical, and Shionogi.

Purchase Inquiries: https://www.alliedmarketresearch.com/purchase-enquiry/5072

The main results of the antibiotic market:
• Based on a broad spectrum of activities, the broad spectrum of antibiotic segments are expected to experience rapid growth in the market and an average annual growth rate of 2.4% from 2018 to 2025.
• Depending on the route of administration, the oral interval is expected to have the highest CAGR during the forecast period.
• Depending on the country of origin of the drug, the semi-synthetic sector was the main source of income in 2017, and this trend is expected to continue during the forecast period.
• The U.S. has the highest revenues, accounting for more than one-fifth of the world market in 2017 in the global antibiotic market in 2017.
• LAMEA is expected to grow at an average annual rate of 3.5% over the forecast period.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.